The British Journal of Clinical Pharmacology

Volume 48
1999

Published for
The British Pharmacological Society by
Blackwell Science

© 1999 Blackwell Science Ltd
Osney Mead, Oxford OX2 0EL
25 John Street, London WC1N 2BL
23 Ainslie Place, Edinburgh EH3 6AJ
Commerce Place, 350 Main Street, Malden MA 02148-5018, USA
54 University Street, Carlton, Victoria 3053, Australia

Other Editorial Offices:
Blackwell Wissenschafts-Verlag GmbH
Kurfürstendamm 57
1707 Berlin
Germany

Blackwell Science KK
MG Kodenmacho Building
7–10 Kodenmacho Nihombashi
Chuo-ku, Tokyo 104
Japan

Published on behalf of
The British Pharmacological Society

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the copyright owner. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Science for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of $14.00 per copy is paid directly to CCC, 222 Rosewood Drive, Suite 910, Danvers, MA 01923, USA. 0206-5251/99 $14.00/0. (For copying beyond that permitted by Sections 107 or 108 of the US Copyright Law). This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Special requests should be addressed to the Editor.

Typeset and printed by The Charlesworth Group, Huddersfield

Contents

Volume 48, Number 1, July 1999

Editorials

1 Clinical pharmacology and therapeutics in a changing world: *D. N. Bateman*

5 Paediatric prescribing: using unlicensed drugs and medicines outside their licensed indications: *J. Collier*

Review

9 Target concentration intervention: beyond Y2K: *N. H. G. Holford*

Drug registration

15 Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use: *P. Impicciatore & I. Choonara*

Clinical trials

19 Transaminase elevation on placebo during phase I trials: prevalence and significance: *P. Rosenzweig, N. Miget & S. Brohier*

25 The prevalence and incidence of medical conditions in healthy pharmaceutical company employees who volunteer to participate in medical research: *S. D. Singh & A. J. Williams*

Pharmacokinetics

33 Netilmicin pharmacokinetics in Hong Kong Chinese cancer patients: *S. Chang, R. C. Li, L. S. Y. Chan, S. Y. Wong, M. Zhu, A. T. C. Chan & K. Raymond*

37 Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children: *R. D. W. Hain, A. Hardcastle, C. R. Pinkerton & G. W. Aherne*

43 Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes: *A. Rostami-Hodjegan, K. Wolff, A. W. M. Hay, D. Raistrick, R. Calvert & G. T. Tucker*

Pharmacodynamics

53 The nasal airways response in normal subjects to oxymetazoline spray: randomized double-blind placebo-controlled trial: *L. Bickford, S. Shakib & D. Taverner*

57 Comparison of antiplatelet activity of microencapsulated aspirin 162.5 mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis: *N. Brown, J. A. May, R. G. Wilcox, L. M. Allan, A. M. Wilson, P. S. Kiff & S. Heptinstall*

Pharmacokinetics/pharmacodynamics

63 Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy: *B. Vadher, D. L. H. Patterson & M. Leaning*

71 Pharmacokinetic and pharmacodynamic characterization of OROS® and immediate-release amitriptyline: *S. K. Gupta, J. C. Shah & S. W. Hwang*

Drug disposition

79 Photoinduced covalent binding of frusemide and frusemide glucuronide to human serum albumin: *T. Mizuma, A. F. McDonagh, E. T. Lin & L. Z. Benet*

89 Zolpidem metabolism *in vitro*: responsible cytochromes, chemical inhibitors, and *in vivo* correlations: *L. L. von Moltke, D. J. Greenblatt, B. W. Granda, S. X. Duan, J. M. Grassi, K. Venkatakrishnan, J. S. Harmatz & R. I. Shader*

Short report

99 Comparison of the vasorelaxant effect of nitroprusside and nitroglycerin in the human radial artery *in vitro*: *G.-W. He & C.-Q. Yang*

Letter to the Editors

105 Drug-induced hyponatraemia in elderly patients: *M. Schwab, F. Röder, K. Mörike, K.-P. Thon & U. Klotz*

107 Phase II trials in drug development: *J. H. Shelley*

Volume 48, Number 2, August 1999

Reviews

109 Antibiotic resistance: a current perspective: *K. F. Barker*

125 LDL particle size: an important drug target?: *I. Rajman, P. I. Eacho, P. J. Chowienczyk & J. M. Ritter*

134 Drug interactions, renal impairment and hypoglycaemia in a patient with Type II diabetes: *M. Collin & J. C. Mucklow*

Opinion

138 Spontaneous reporting — of what? Clinical concerns about drugs: *I. R. Edwards*

Drug absorption

142 Paroxetine in human milk: *E. J. Begg, S. B. Duffull, D. A. Saunders, R. C. Buttimore, K. F. Ilett, L. P. Hackett, P. Yapp & D. A. Wilson*

148 Effect of activated charcoal alone or given after gastric lavage in reducing the absorption of diazepam, ibuprofen and citalopram: *O. Lapatto-Reiniluoto, K. T. Kivistö & P. J. Neuvonen*

Pharmacokinetics

154 Plasma concentrations of disodium cromoglycate after various inhalation methods in healthy subjects: *Y. Kato, K. Muraki, M. Fujitaka, N. Sakura & K. Ueda*

Pharmacogenetics

158 Comparison of (S)-mephenytoin and proguanil oxidation *in vitro*: contribution of several CYP isoforms: *J. K. Coller, A. A. Somogyi & F. Bochner*

Drug interactions

168 Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients: *K. D. Gallicano, J. Sahai, V. K. Shukla, I. Seguin, A. Pakuts, D. Kwok, B. C. Foster & D. W. Cameron*

80 The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans: *R. Sandström, T. W. Knutson, L. Knutson, B. Jansson & H. Lennernäs*

190 The effects of moclobemide on the pharmacokinetics of the 5-$HT_{1B/1D}$ agonist rizatriptan in healthy volunteers: *A. D. van Haarst, J. M. A. van Gerven, A. F. Cohen, M. De Smet, A. Sterrett, K. L. Birk, A. L. Fisher, M. E. De Puy, M. R. Goldberg & D. G. Musson*

Pharmacodynamics

197 Platelet glycoprotein IIb/IIIa blockade with tirofiban: effect on aggregation caused by P256, an antibody to human IIb/IIIa receptors: *I. Fisher, P. Robinson & J. M. Ritter*

200 A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function: *I. Hindmarch, Z. Shamsi, N. Stanley & D. B. Fairweather*

Vascular pharmacodynamics

207 Inhibition of vasoconstriction by the thromboxane A_2 antagonist GR32191B in the human radial artery: *G.-W. He & C.-Q. Yang*

216 Histamine response and local cooling in the human skin: involvement of H_1- and H_2-receptors: *M. Grossmann, M. J. Jamieson & W. Kirch*

223 Relaxant effects of antidepressants on human isolated mesenteric arteries: *J. M. Vila, P. Medina, G. Segarra, P. Lluch, F. Pallardó, B. Flor & S. Lluch*

Pharmacoepidemiology

230 Cohort study on calcium channel blockers, other cardiovascular agents, and the prevalence of depression: *N. R. Dunn, S. N. Freemantle & R. D. Mann*

234 Risk of malformations and other outcomes in children exposed to fluconazole *in utero*: *H. T. Sørensen, G. L. Nielsen, C. Olesen, H. Larsen, F. H. Steffensen, H. C. Schønheyder, J. Olsen & A. E. Czeizel*

239 Drug and Therapeutics (D & T) committees in Dutch hospitals: a nation-wide survey of structure, activities, and drug selection procedures: *R. Fijn, J. R. B. J. Brouwers, R. J. Knaap & L. T. W. De Jong-Van den Berg*

Short reports

247 Withdrawal of peripheral vasodilators in primary care: *D. Stewart, J. Krska, K. Kendle, D. Wintour & C. McGregor*

250 The pharmacokinetics of lamivudine in healthy Chinese subjects: *J. Jiang, P. Hu, H. Xie, H. Chen, F. Fan, A. Harker & M. A. Johnson*

254 Serum concentrations of tramadol enantiomers during patient-controlled analgesia: *S. Grond, T. Meuser, H. Uragg, H. J. Stahlberg & K. A. Lehmann*

258 Flow ratios to express results obtained with the human *in vivo* 'perfused forearm technique': *G. A. Rongen, G. Lambrou & P. Smits*

262 The treatment of eczema with Chinese herbs: a systematic review of randomized clinical trials: *N. C. Armstrong & E. Ernst*

Volume 48, Number 3, September 1999

Reviews

265 A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer: *A. A. Adjei*

278 Therapeutic drug monitoring in drug overdose: *A. H. Dawson & I. M. Whyte*

284 Emergency management of acute myocardial infarction: *S. R. J. Maxwell*

Pharmacokinetics

299 Pharmacokinetics of bambuterol during oral administration to asthmatic children: *H. Ahlström, J. Alvero, R. Alvero, R. Espos, L. Fajutrao, J. Herrera, B. Kjellman, J. Kubista, C. Leviste, P. Meyer, G. Oldæus, A. Siricururat, P. Vichyanond, G. Wettrell, E. Wong, L. Laxmyr, L. Nyberg, H. Olsson, E. Weibull & J. Rosenborg*

309 Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler®: *H. Kaiser, D. Aaronson, R. Dockhorn, S. Edsbäcker, P. Korenblat & A. Källén*

317 Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing: *S. Ammon, U. Hofmann, E.-U. Griese, N. Gugeler & G. Mikus*

Pharmacodynamics

323 Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers: *A. M. Hughes, P. Lynch, J. Rhodes, C. M. Ervine & R. A. Yates*

331 Changes in systolic time intervals—a noninvasive marker for the haemodynamic effects of sumatriptan: *S. Hood*

336 Substance P induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man: *D. E. Newby, D. G. Sciberras, C. J. Ferro, B. J. Gertz, D. Sommerville, A. Majumdar, R. C. Lowry & D. J. Webb*

345 Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein: *A. H. Abdelmawla, R. W. Langley, E. Szabadi & C. M. Bradshaw*

355 The effect of nitric oxide inhibition on the renin response to frusemide, in man: *A. F. C. Lee, D. G. Kiely, W. J. Coutie & A. D. Struthers*

361 The influence of frusemide formulation on diuretic effect and efficiency: *M. Wakelkamp, Å. Blechert, M. Eriksson, K. Gjellan & C. Graffner*

367 A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening: *P. Danjou, I. Paty, R. Fruncillo, P. Worthington, M. Unruh, W. Cevallos & P. Martin*

Pharmacokinetics/pharmacodynamics

375 Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics: *P. O'Grady, K.-F. Yee, R. Lins & B. Mangold*

382 The antitussive effect of dextromethorphan in relation to CYP2D6 activity: *R. A. Manap, C. E. Wright, A. Gregory, A. Rostami-Hodjegan, S. T. Meller, G. R. Kelm, M. S. Lennard, G. T. Tucker & A. H. Morice*

Pharmacogenetics

388 Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation: *K. J. Aitchison, J. Munro, P. Wright, S. Smith, A. J. Makoff, C. Sachse, P. C. Sham, R. M. Murray, D. A. Collier & R. W. Kerwin*

395 Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population: *L. Bathum*

402 Genetic polymorphism of (S)-mephenytoin 4′-hydroxylation in populations of African descent: *H. G. Xie, R. B. Kim, C. M. Stein, G. R. Wilkinson & A. J. J. Wood*

409 Frequency of cytochrome P450 *CYP2C9* variants in a Turkish population and functional relevance for phenytoin: *A. S. Aynacioglu, J. Brockmöller, S. Bauer, C. Sachse, P. Güzelbey, Z. Öngen, M. Nacak & I. Roots*

Drug metabolism and disposition

416 Evidence for involvement of polymorphic CYP2C19 and 2C9 in the *N*-demethylation of sertraline in human liver microsomes: *H. H. Zhou*

424 Characterization of the cytochrome P450 enzymes in the *in vitro* metabolism of rosiglitazone: *S. J. Baldwin, S. E. Clarke & R. J. Chenery*

Pharmacovigilance

433 Achilles tendinitis associated with fluoroquinolones: *B. H. Stricker*

Drug interaction

438 Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline: *U. Klotz*

Short reports

445 Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients: *Y. Böttiger, C. Brattström, G. Tydén, J. Säwe & C.-G. Groth*

449 COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients on levodopa/cardidopa (Sinemet®): *K. M. Jorga & D. J. Nicholl*

453 Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers: *I. Ragueneau, J.-M. Poirier, N. Radembino, A. Buu Sao, C. Funck-Brentano & P. Jaillon*

457 Forearm reactive hyperaemia is not mediated by nitric oxide in health volunteers: *A. G. Nugent, C. McGurk, D. McAuley, S. Maguire, B. Silke & G. D. Johnston*

460 The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension: *M. Dawes, S. E. Brett, P. J. Chowienczyk, T. G. K. Mant & J. M. Ritter*

Letters to the Editors

464 Blood pressure and renin angiotensis system responds to initiation of treatment with captopril or losartan in heart failure: *I. B. Squire, S. Robb, G. Brennan, K. P. J. O'Kane, H. J. Dargie & J. L. Reid*

465 Subtherapeutic levels of phenytoin with standard doses in infants: need to review dosage schedule: *C. T. Rane*

Book reviews

467 Advances in drug delivery techniques: *J. Steiner*

467 Psychiatric disorders with a biochemical basis: *P. Bennett*

469 Errata

Volume 48, Number 4, October 1999

Reviews

471 Acetylcholinesterase inhibitors in alzheimer's disease: *B. M. McGleenon, K. B. Dynan & A. P. Passmore*

481 Nicotine treatment for ulcerative colitis: *M. Guslandi*

Pharmacokinetics

485 An oral formulation of nicotine for release and absorption in the colon: its development and pharmacokinetics: *J. T. Green, B. K. Evans, J. Rhodes, G. A. O. Thomas, C. Ranshaw, C. Feyerabend & M. A. H. Russell*

494 Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination: *N. G. Grubb, D. W. Rudy, D. C. Brater & S. D. Hall*

Pharmacokinetics/pharmacodynamics

501 Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects: *K. Turnheim, P. Krivanek & R. Oberbauer*

510 Pharmacokinetic–pharmacodynamic analysis of mnesic effects of lorazepam in healthy volunteers: *O. Blin, A. Jacquet, S. Callamand, E. Jouve, M. Habib, D. Gayraud, A. Durand, B. Bruguerolle & P. Pisano*

Drug disposition

513 Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase: *K. Jorga, B. Fotteler, P. Heizmann & R. Gasser*

521 Distribution and excretion of fluoxetine and norfluoxetine in human milk: *J. H. Kristensen, K. F. Ilett, L. P. Hackett, P. Yapp, M. Paech & E. J. Begg*

528 Identification of the human cytochrome P450 enzymes involved in the *in vitro* metabolism of artemisinin: *U. S. H. Svensson & M. Ashton*

Drug–food interactions

536 The effect of dosing regimen on the pharmacokinetics of risedronate: *D. Y. Mitchell, M. A. Heise, K. A. Pallone, M. E. Clay, J. D. Nesbitt, D. A. Russell & C. W. Melson*

543 Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components: *V. A. Eagling, L. Profit & D. J. Back*

Drug–drug interactions

553 Fluoxetine inhibits the metabolism of tolterodine — pharmacokinetic implications and proposed clinical relevance: *N. Brynne, C. Svanström, A. Åberg-Wistedt, B. Hallén & L. Bertilsson*

564 Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity: *N. Brynne, C. Forslund, B. Hallén, L. L. Gustafsson & L. Bertilsson*

Pharmacodynamics

573 Lymphocyte-sensitivity to glucocorticoid correlates with the sensitivity to cyclosporin A and tacrolimus in chronic renal failure patients: *A. Horigome, T. Hirano, K. Oka, H. Takeuchi, E. Sakurai, K. Kozaki, N. Matsuno, T. Nagao & M. Kozaki*

579 Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults: *A. M. Wilson & B. J. Lipworth*

Vascular pharmacodynamics

586 Evaluation of noninvasive blood pressure recording by photoplethysmography in clinical studies using angiotensin challenges: *T. Buclin, C. Buchwalder-Csajka, H. R. Brunner & J. Biollaz*

594 Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system: *C. Buchwalder-Csajka, T. Buclin, H. R. Brunner & J. Biollaz*

Lipid lowering therapy

605 Acarbose is an effective adjuct dietary therapy in the treatment of hypertriglyceridaemias: *M. Malaguarnera, I. Giugno, P. Ruello, M. Rizzo, M. Motta & G. Mazzoleni*

610 Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients: *K. Rowland Yeo, W. W. Yeo, E. J. Wallis & L. E. Ramsay*

Pharmacoepidemiology

616 Impact of guidelines implemented in a Paris university hospital: application to the use of antiemetics by cancer patients: *I. Debrix, A. Flahault, A. Becker, L. Schwartz, A. Kanfer & B. Milleron*

623 Attitudinal survey of voluntary reporting of adverse drug reactions: *I. A. Eland, K. J. Belton, A. C. van Grootheest, A. P. Meiners, M. D. Rawlins & B. H. Ch. Stricker*

Short reports

628 Persistence of anti-hypertensive effect after missed dose of perindopril: *K. W. Tan & F. H. H. Leenen*

631 Fenoterol stimulates human erythropoietin production via activation of the renin angiotensin system: *S. M. Freudenthaler, T. Schenck, I. Lucht & C. H. Gleiter*

635 Absorption of sunscreens across human skin: an evaluation of commercial products for children and adults: *R. Jiang, M. S. Roberts, D. M. Collins & H. A. E. Benson*

638 Possible enhancement of the first-pass metabolism of phenacetin by ingestion of grape juice in Chinese subjects: *S. Xiao Dong, Z. Zhi Ping, W. Zhong Xiao, C. Chong Shu, C. Fattore, G. Gatti, S. D'Urso & E. Perucca*

Book review

641 Side-effects of drugs: Annual 21: *K. Beard*

Volume 48, Number 5, November 1999

Reviews

643 The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes: *P. King, I. Peacock & R. Donnelly*

649 Therapeutic drug monitoring in a developing country: an overview: *N. J. Gogtay, N. A. Kshirsagar & S. S. Dalvi*

Drug disposition

655 Effect of chronic magnesium supplementation on magnesium distribution in healthy volunteers evaluated by ^{31}P NMRS and ion selective electrodes: *C. Wary, C. Brillault-Salvat, G. Bloch, A. Leroy-Willig, D. Roumenov, J.-M. Grognet, J. H. Leclerc & P. G. Carlier*

663 Tacrine is not an ideal probe drug for measuring CYP1A2 activity *in vivo*: *J. T. Larsen, L. L. Hansen & K. Brøsen*

Pharmacokinetics

669 Pharmacokinetics and tolerability of JTE-522, a novel selective cyclooxygenase-2 inhibitor, in healthy male volunteers: *K. Umemura, K. Kondo, Y. Ikeda, M. Nakashima, T. Kobayashi, M. Takahashi & T. Yokoyama*

678 Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation: *M. Chung, V. Vashi, J. Puente, M. Sweeney & P. Meredith*

688 Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease: *Y. Preechagoon, B. Charles, V. Piotrovskij, T. Donovan & A. Van Peer*

694 Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients: *H.-H. Neumayer, K. Paradis, A. Korn, C. Jean, L. Fritsche, K. Budde, M. Winkler, V. Kliem, R. Pichlmayr, I. A. Hauser, K. Burkhardt, A.-E. Lison, I. Barndt & S. Appel-Dingemanse*

Pharmacokinetics in HIV infection

704 Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome: *G. Gatti, A. Di Biagio, C. R. De Pascalis, M. Guerra, M. Bassetti & D. Bassetti*

712 Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients: *P. Villani, M. B. Regazzi, F. Castelli, P. Viale, C. Torti, E. Seminari & R. Maserati*

Drug interactions

716 CYP3A4 drug interactions: correlation of 10 *in vitro* probe substrates: *K. E. Kenworthy, J. C. Bloomer, S. E. Clarke & J. B. Houston*

728 Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride: *S. Kechagias, K.-Å. Jönsson & A. W. Jones*

733 Effects of cytochrome P450 inducers on 17α-ethinyloestradiol (EE_2) conjugation by primary human hepatocytes: *A. P. Li, N. R. Hartman, C. Lu, J. M. Collins & J. M. Strong*

Pharmacokinetics/pharmacodynamics

743 Myocardial region (right or left ventricle) and aetiology of heart failure can influence the inotropic effect of ouabain in failing human myocardium: *R. Padrini, M. Panfili, G. Magnolfi, D. Piovan, D. Casarotto & M. Ferrari*

750 Rapid development of tolerance to dipyridamole-associated headaches: *J. G. W. Theis, G. Deichsel & S. Marshall*

Short reports

756 Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study: *P. O. Lim, R. T. Jung & T. M. MacDonald*

761 Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the β_2-adrenergic receptor among Turks: *A. S. Aynacioglu, I. Cascorbi, K. Güngör, M. Özkur, N. Bekir, I. Roots & J. Brockmöller*

Book review

765 A Guide to Training in Clinical Pharmacology in Europe: *D. N. Bateman*

Proceedings

766P Proceedings of the Dutch Society for Clinical Pharmacology and Biopharmacy, 20 April 1999

Volume 48, Number 6, December 1999

Review

785 The selective oestrogen receptor modulation: evolution and clinical applications: *D. W. Purdie & S. A. Beardsworth*

Pharmacokinetics/pharmacodynamics

793 Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine: *T. Dervieux, Y. Médard, V. Baudouin, A. Maisin, D. Zhang, F. Broly, C. Loirat & E. Jacqz-Aigrain*

801 Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers: *E. Bellissant & J.-F. Giudicelli*

Drug disposition

811 Glucuronidation and sulphation of paracetamol in HIV-positive patients and patients with AIDS: *W. M. O'Neil, J. C. Pezzullo, A. Di Girolamo, C. M. Tsoukas & I. W. Wainer*

Drug interactions

819 Lack of interaction between thioctic acid, glibenclamide and acarbose: *C. H. Gleiter, K. H. Schreeb, S. Freudenthaler, M. Thomas, M. Elze, H. Fieger-Büschges, H. Potthast, E. Schneider, B. S. Schug, H. H. Blume & R. Hermann*

826 Effects of bupivacaine on human erythrocytes submitted to stress and evidence for an interaction between bupivacaine and flumazenil: *F. Lenfant, J. J. Lahet, F. Volot, I. Schafer, M. Freysz & L. Rochette*

829 Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine: *P. Damkier, L. L. Hansen & K. Brøsen*

Pharmacovigilance

839 Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions: *L. Naldi, A. Conforti, M. Venegoni, M. G. Troncon, A. Caputi, E. Ghiotto, A. Cocci, U. Moretti, G. Velo & R. Leone*

847 A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs: *L. A. García Rodríguez, A. Duque, J. Castellsague, S. Pérez-Gutthann & B. H. Ch. Stricker*

Therapeutics

853 Placebo effect in the treatment of duodenal ulcer: *A. J. M. De Craen, D. E. Moerman, S. H. Heisterkamp, G. N. J. Tytgat, J. G. P. Tijssen & J. Kleijnen*

Short reports

861 Angiodema due to ACE inhibitors: increased risk in patients of African origin: *C. R. Gibbs, G. Y. H. Lip & D. G. Beevers*

866 Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate: *B. J. Lipworth & C. M. Jackson*

Letter to the Editors

869 Effect of gamma-linolenic acid on plasma and membrane lipids and renal prostaglandins in old subjects: *A. Hornych, F. Girault, S. Oravec, B. Forette & D. F. Horrobin*

Proceedings

871 Proceedings of the British Pharmacological Society, 14–16 July 1999, Nottingham

892 Indexes to Volume 48